Curis Inc.
(NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted blood cancers.
Read Also: Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity Strong Efficacy Data In Primary CNS Lymphoma Trial In the registrational TakeAim Lymphoma study targeting Primary CNS Lymphoma, data through July 1, 2026, demonstrated solid response rates.
Central nervous system (CNS) lymphoma is a rare, aggressive form of non-Hodgkin lymphoma that starts in the brain, spinal cord, cerebrospinal fluid, or eyes.
